232 related articles for article (PubMed ID: 23404447)
1. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study.
Stragliotto G; Rahbar A; Solberg NW; Lilja A; Taher C; Orrego A; Bjurman B; Tammik C; Skarman P; Peredo I; Söderberg-Nauclér C
Int J Cancer; 2013 Sep; 133(5):1204-13. PubMed ID: 23404447
[TBL] [Abstract][Full Text] [Related]
2. Immortal time bias in retrospective analysis: is there a survival benefit in patients with glioblastoma who received prolonged treatment of adjuvant valganciclovir?
Liu CJ; Hu YW
Int J Cancer; 2014 Jul; 135(1):250-1. PubMed ID: 24338590
[No Abstract] [Full Text] [Related]
3. Cytomegalovirus and glioblastoma: a review of evidence for their association and indications for testing and treatment.
Solomon IH; Ramkissoon SH; Milner DA; Folkerth RD
J Neuropathol Exp Neurol; 2014 Nov; 73(11):994-8. PubMed ID: 25289896
[TBL] [Abstract][Full Text] [Related]
4. Use of Cox regression with treatment status as a time-dependent covariate to re-analyze survival benefit excludes immortal time bias effect in patients with glioblastoma who received prolonged adjuvant treatment with valganciclovir.
Söderberg-Naucler C; Peredo I; Rahbar A; Hansson F; Nordlund A; Stragliotto G
Int J Cancer; 2014 Jul; 135(1):248-9. PubMed ID: 24338548
[No Abstract] [Full Text] [Related]
5. Does valganciclovir have a role in glioblastoma therapy?
Cobbs CS
Neuro Oncol; 2014 Mar; 16(3):330-1. PubMed ID: 24523453
[No Abstract] [Full Text] [Related]
6. The legend of cytomegalovirus and glioblastoma lives on.
Weller M; Soffietti R; Brada M
Neuro Oncol; 2014 Jan; 16(1):166. PubMed ID: 24311642
[No Abstract] [Full Text] [Related]
7. Controversies in neuro-oncology: does valganciclovir have a role in the treatment of high-grade gliomas?
Wen PY
Neuro Oncol; 2014 Mar; 16(3):329. PubMed ID: 24523452
[No Abstract] [Full Text] [Related]
8. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation.
Montesinos P; Sanz J; Cantero S; Lorenzo I; Martín G; Saavedra S; Palau J; Romero M; Montava A; Senent L; Martínez J; Jarque I; Salavert M; Córdoba J; Gómez L; Weiss S; Moscardó F; de la Rubia J; Larrea L; Sanz MA; Sanz GF
Biol Blood Marrow Transplant; 2009 Jun; 15(6):730-40. PubMed ID: 19450758
[TBL] [Abstract][Full Text] [Related]
9. Ganciclovir concentrations in the cerebral extracellular space after valganciclovir treatment; a case study.
Peredo I; Helldén A; Wolmer-Solberg N; Pohanka A; Stragliotto G; Rahbar A; Ståhle L; Bellander BM; Söderberg-Nauclér C
BMJ Case Rep; 2015 Dec; 2015():. PubMed ID: 26670887
[TBL] [Abstract][Full Text] [Related]
10. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
[TBL] [Abstract][Full Text] [Related]
11. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
12. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial.
Casper C; Krantz EM; Corey L; Kuntz SR; Wang J; Selke S; Hamilton S; Huang ML; Wald A
J Infect Dis; 2008 Jul; 198(1):23-30. PubMed ID: 18491970
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
Reischig T; Kacer M; Jindra P; Hes O; Lysak D; Bouda M
Clin J Am Soc Nephrol; 2015 Feb; 10(2):294-304. PubMed ID: 25424991
[TBL] [Abstract][Full Text] [Related]
14. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.
Martin DF; Sierra-Madero J; Walmsley S; Wolitz RA; Macey K; Georgiou P; Robinson CA; Stempien MJ;
N Engl J Med; 2002 Apr; 346(15):1119-26. PubMed ID: 11948271
[TBL] [Abstract][Full Text] [Related]
15. CMV infection and glioma, a highly controversial concept struggling in the clinical arena.
Wick W; Platten M
Neuro Oncol; 2014 Mar; 16(3):332-3. PubMed ID: 24523454
[No Abstract] [Full Text] [Related]
16. Oral Valganciclovir Initiated Beyond 1 Month of Age as Treatment of Sensorineural Hearing Loss Caused by Congenital Cytomegalovirus Infection: A Randomized Clinical Trial.
Kimberlin DW; Aban I; Peri K; Nishikawa JK; Bernatoniene J; Emonts M; Klein N; Bamford A; DeBiasi RL; Faust SN; Jones CE; McMaster P; Caserta M; Ahmed A; Sharland M; Demmler-Harrison G; Hackett S; Sánchez PJ; Shackley F; Kelly D; Dennehy PH; Storch GA; Whitley RJ; Griffiths P;
J Pediatr; 2024 May; 268():113934. PubMed ID: 38309519
[TBL] [Abstract][Full Text] [Related]
17. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients.
Humar A; Siegal D; Moussa G; Kumar D
J Infect Dis; 2005 Oct; 192(7):1154-7. PubMed ID: 16136456
[TBL] [Abstract][Full Text] [Related]
18. Survival in patients with glioblastoma receiving valganciclovir.
Söderberg-Nauclér C; Rahbar A; Stragliotto G
N Engl J Med; 2013 Sep; 369(10):985-6. PubMed ID: 24004141
[No Abstract] [Full Text] [Related]
19. Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial.
Finlen Copeland CA; Davis WA; Snyder LD; Banks M; Avery R; Davis RD; Palmer SM
J Heart Lung Transplant; 2011 Sep; 30(9):990-6. PubMed ID: 21489817
[TBL] [Abstract][Full Text] [Related]
20. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
Boivin G; Goyette N; Gilbert C; Roberts N; Macey K; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Covington E
J Infect Dis; 2004 May; 189(9):1615-8. PubMed ID: 15116297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
